MIM
ALXN

MetLife Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

MetLife Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,524
Closed -$9.28M – 2601
2021
Q2 		$9.28M Sell
50,524
-1,153
-2% -$198K 0.08% 204
2021
Q1 		$7.9M Sell
51,677
-760
-1% -$118K 0.07% 238
2020
Q4 		$8.19M Sell
52,437
-2,410
-4% -$310K 0.08% 217
2020
Q3 		$6.28M Sell
54,847
-2,422
-4% -$261K 0.07% 257
2020
Q2 		$6.43M Buy
57,269
+229
+0.4% +$24.3K 0.07% 237
2020
Q1 		$5.12M Sell
57,040
-1,746
-3% -$171K 0.07% 242
2019
Q4 		$6.36M Sell
58,786
-2,234
-4% -$239K 0.07% 265
2019
Q3 		$5.98M Sell
61,020
-788
-1% -$88.8K 0.07% 277
2019
Q2 		$8.1M Sell
61,808
-1,703
-3% -$219K 0.09% 207
2019
Q1 		$8.59M Sell
63,511
-278
-0.4% -$34.6K 0.09% 198
2018
Q4 		$6.21M Sell
63,789
-1,029
-2% -$122K 0.08% 231
2018
Q3 		$9.01M Sell
64,818
-681
-1% -$85.4K 0.09% 195
2018
Q2 		$8.13M Sell
65,499
-1,213
-2% -$142K 0.1% 183
2018
Q1 		$7.44M Sell
66,712
-2,413
-3% -$288K 0.09% 208
2017
Q4 		$8.27M Buy
+69,125
New +$8.42M 0.09% 193

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

MetLife Investment Management's ALXN Position: Q3 2021 in Review

MetLife Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 50,524 shares — an estimated $9.28M sold.

MetLife Investment Management first reported a position in ALXN in Q4 2017 and held it in 15 quarters. The position peaked at $9.28M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • MetLife Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • MetLife Investment Management sold 50,524 Alexion Pharmaceuticals shares in Q3 2021, an estimated $9.28M.
  • MetLife Investment Management first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 15 quarters.
  • MetLife Investment Management's Alexion Pharmaceuticals position peaked at $9.28M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on MetLife Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.